Chugai Ups Forecast On Star Performer Hemlibra
Roche affiliate substantially raises full-year forecast following double-digit sales and profit growth, mainly on the back of strength for hemophilia drug Hemlibra.
You may also be interested in...
Japanese firm unveils major restructuring of R&D sites in Japan through a new $1bn core lab set to open in early 2023 and the closure of two other long-established facilities.
Japan approves a batch of new products and indications, including Daiichi Sankyo's Enhertu in a high-need indication after a rapid review and Takeda's Zejula, which will be made available to selected patients before its reimbursement listing.
Join us for an audio roundup of major events in the global biopharma industry over the past week, as reported by Scrip.